12:00 AM
Oct 01, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Adcetris brentuximab vedotin: Completed Phase III enrollment

Seattle Genetics and Takeda's Millennium Pharmaceuticals Inc. subsidiary completed enrollment of 329 patients in the double-blind, placebo-controlled, international Phase III AETHERA trial evaluating Adcetris brentuximab vedotin every 3 weeks for up to 1 year following autologous stem cell transplant (ASCT). In August 2011, FDA granted accelerated approval for Adcetris to treat Hodgkin's lymphoma and anaplastic large cell lymphoma (ALCL). As part of the...

Read the full 305 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >